Interleukin-18, matrix metalloproteinase-22 and -29 are independent risk factors of human coronary heart disease

Interleukin-18, matrix metalloproteinase-22 and -29 are independent risk factors of human coronary heart disease 白细胞介素18、基质金属蛋白酶-22及-29与冠心病发生风险的关联研究 1 first-author 1 2 1 3 4 1 1 1 5 1 1 1 2 corresp ‡Corresponding Author ‡Corresponding Author †E-mail:gshi@bwh.harvard.edujyzhang@zzu.edu.cn †E-mail:gshi@bwh.harvard.edujyzhang@zzu.edu.cn gshi@bwh.harvard.edu 1 corresp ‡Corresponding Author ‡Corresponding Author †E-mail:gshi@bwh.harvard.edujyzhang@zzu.edu.cn †E-mail:gshi@bwh.harvard.edujyzhang@zzu.edu.cn gshi@bwh.harvard.edu Department of Cardiology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China Department of Cardiology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115, USA Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115, USA Department of Molecular Biomedical Sciences and Center for Comparative Medicine and Translational Research, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27695, USA Department of Molecular Biomedical Sciences and Center for Comparative Medicine and Translational Research, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27695, USA Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA Department of Biology, Pennsylvania State University, University Park, PA 16802, USA Department of Biology, Pennsylvania State University, University Park, PA 16802, USA Background: 2 Coronary heart disease (CHD) is characterized by arterial wall inflammation and matrix degradation. Matrix metalloproteinase (MMP)-22 and -29 and pro-inflammatory cytokine interleukin-18 (IL18) are present in human hearts. IL18 may regulate MMP-22 and -29 expression, which may correlate with CHD progression. Methods and results: 2 Immunoblot analysis showed that IL18 induced MMP-22 expression in human aortic smooth muscle cells. The Mann Whitney test from a prospective study of 194 CHD patients and 68 non-CHD controls demonstrated higher plasma levels of IL18, MMP-22 and -29 in CHD patients than in the controls. A logistic regression test suggested that plasma IL18 (odds ratio (OR)=1.131, P =0.007), MMP-22 (OR=1.213, P =0.040), and MMP-29 (OR=1.198, P =0.033) were independent risk factors of CHD. Pearson’s correlation test showed that IL18 (coefficient ( r )=0.214, P =0.045; r =0.246, P =0.031) and MMP-22 ( r =0.273, P =0.006; r =0.286, P =0.012) were associated with the Gensini score before and after adjusting for potential confounding factors. The multivariate Pearson’s correlation test showed that plasma MMP-22 levels correlated positively with high-sensitive-C-reactive protein (hs-CRP) ( r =0.167, P =0.023), and MMP-29 levels correlated negatively with triglyceride ( r =−0.169, P =0.018). Spearman’s correlation test indicated that plasma IL18 levels associated positively with plasma MMP-22 ( r =0.845, P < 0.001) and MMP-29 ( r =0.548, P < 0.001). Conclusions: 2 Our observations suggest that IL18, MMP-22 and -29 serve as biomarkers and independent risk factors of CHD. Increased systemic IL18 in CHD patients may contribute to elevated plasma MMP-22 and -29 levels in these patients. 目的 2 探讨冠心病患者血浆白细胞介素18（IL18）水平是否与基质金属蛋白酶-22和-29（MMP-22和MMP-29）的表达水平相关，以及此类患者血浆中MMP-22及MMP-29水平是否升高。 创新点 2 首次证实在动脉粥样硬化过程中炎症反应可能促进MMP-22及MMP-29的表达，IL18是冠心病患者中调控MMP表达的炎症因子之一。 方法 2 通过免疫印迹分析检测IL18对人体动脉平滑肌细胞MMP-22的表达；通过Mann Whitney检验对来自于194例冠心病患者和68例对照组的前瞻性研究进行分析；通过logistic回归分析冠心病的独立风险因素；通过Pearson相关性分析IL18和MMP-22的表达水平与冠状动脉Gensini积分的相关性；通过多变量Pearson相关性分析血浆MMP-22水平与超敏C反应蛋白（hs-CRP）及甘油三酯水平的相关性；通过Spearman相关性分析血浆IL18水平与MMP-22和MMP-29的相关性。 结论 2 冠心病患者血浆IL18水平升高可能导致此类患者血浆MMP-22和MMP-29水平升高。IL18、MMP-22和MMP-29可能是冠心病的生物标记物和独立风险因素。 Interleukin-18 Matrix metalloproteinase (MMP)-22 MMP-29 Coronary heart disease Risk factor 白细胞介素18 基质金属蛋白酶-22 基质金属蛋白酶-29 冠心病 风险因素 Introduction 1 Coronary heart disease (CHD) remains the leading cause of death worldwide (Pagidipati and Gaziano, 2013 2013 ). Recent studies have underscored the importance of detecting, monitoring, and controlling the vulnerability of atherosclerotic plaques to reduce the mortality rate among CHD patients (Cheng et al., 2006 2006 ; Libby et al., 2009 2009 ; Finn et al., 2010 2010 ; Arbab-Zadeh and Fuster, 2015 2015 ). Inflammatory cell accumulation and production of inflammatory cytokines are key processes that contribute to the initiation, progression, and ultimately the rupture and thrombosis of atherosclerotic plaques (Ross, 1999 1999 ; Hansson, 2005 2005 ; Libby et al., 2009 2009 ). Arterial wall extracellular matrix (ECM) protein degradation is one of the most prominent mechanisms of aortic atherosclerotic lesion growth and rupture, in which matrix metalloproteinases (MMPs) are among the common proteases (Herman et al., 2001 2001 ; Katsuda and Kaji, 2003 2003 ; Newby, 2005 2005 ; Siasos et al., 2012 2012 ). Previous studies showed significantly elevated plasma levels of pro-inflammatory cytokine interleukin-18 (IL18) in patients who developed coronary events. Plasma IL18 has been considered as an inflammatory risk factor of human CHD (Blankenberg et al., 2002 2002 ; 2003 2003 ; Evans et al., 2007 2007 ; Jefferis et al., 2011 2011 ; 2013 2013 ). In addition to its systemic increases, IL18 expression was also found increased in human and experimental atherosclerotic lesions (Mallat et al., 2001 2001 ; Gerdes et al., 2002 2002 ; Wang et al., 2015 2015 ). In mouse experimental models, deficiency of IL18 or IL18 receptors protected mice from diet-induced atherosclerosis (Elhage et al., 2003 2003 ; Wang et al., 2015 2015 ). Intraperitoneal administration of recombinant IL18 accelerated atherogenesis in mice (Tenger et al., 2005 2005 ). Our recent study suggested that IL18 contributes to atherogenesis by inducing inflammatory cell (e.g. macrophages and T cells) production of inflammatory cytokines and chemokines, such as IL6, interferon-γ (IFN-γ), and monocyte chemoattractant protein-1 (MCP-1) (Wang et al., 2015 2015 ). IL18 is also a known inducer of MMP expression from inflammatory cells, such as natural killer (NK) cell (Ishida et al., 2004 2004 ), monocytes and macrophages (Quiding-Jarbrink et al., 2001 2001 ; Abraham et al., 2002 2002 ; Gerdes et al., 2002 2002 ), and cardiomyocytes (Reddy et al., 2010 2010 ). MMPs are highly expressed in various pathological processes, such as inflammation, myocardial injury, and vascular aneurysms and remodeling (Creemers et al., 2001 2001 ). Several major MMPs, such as MMP-1, -2, -7, -9, and -12 have been shown to be increased in the plasma or atherosclerotic lesions from CHD patients (Loftus et al., 2001 2001 ; Nilsson et al., 2006 2006 ; Lehrke et al., 2009 2009 ; Ma et al., 2014 2014 ; Goncalves et al., 2015 2015 ). Genetic depletion or pharmacological inhibition of these MMPs protected mice from experimental atherosclerosis (Luttun et al., 2004 2004 ; Kuzuya et al., 2006 2006 ; Johnson et al., 2011 2011 ; Hu et al., 2015 2015 ). Human MMP-22 was first identified from human testis and heart. Northern blot detection showed its dominant expression in the human heart (Gururajan et al., 1998 1998 ). Alternative splicing yielded three MMP-22 isoforms that differ in length of exon 4 or 5 (Gururajan et al., 1998 1998 ). However, there is no further study to report its function or expression regulation in any tissue, cell type, or pathological condition. Human MMP-29 was also initially isolated from a human testis complementary DNA (cDNA) library, but it is more broadly expressed than MMP-22. Small intestine, liver, heart, kidney, and many other organs express this MMP (Wu et al., 2007 2007 ). In addition to these initial expression profiles, there is no study to test the role of MMP-29 in the heart or vascular system. As atherosclerosis is a chronic inflammatory disease of the aortic artery and inflammation may induce the expression of these underestimated MMP members (Mallat et al., 2001 2001 ; Blankenberg et al., 2002 2002 ; 2003 2003 ; Gerdes et al., 2002 2002 ; Evans et al., 2007 2007 ; Jefferis et al., 2011 2011 ; 2013 2013 ; Wang et al., 2015 2015 ), we designed this study to test whether increased plasma and arterial wall inflammatory cytokine IL18 in CHD patient was correlated with or affected the expression of MMP-22 and -29, and whether plasma levels of these MMPs were also increased in CHD patients. Materials and methods 1 Cell culture and Western blot 2 Human macrophages were prepared by differentiating Ficoll gradient-separated monocytes from human peripheral blood mononuclear cells in Roswell Park Memorial Institute 1640 (RPMI 1640) with 10% human serum (Gemini Bio-Products, Broderick, CA, USA) for 14 d on Falcon Primaria tissue culture dishes (Becton, Dickinson and Company, Franklin Lakes, NJ, USA). Human aortic smooth muscle cells (SMCs) were obtained from human donor aortas and subcultured at passages 2–5 in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS). Use of human primary cells or discarded tissues was pre-approved by the Partners Human Research Committee, Brigham and Women’s Hospital (Boston, MA, USA). For Western blot, human macrophages were starved for 24 h using serum-free RPMI 1640, followed by the addition of recombinant mouse IL18 (50 ng/ml, MBL International, Woburn, MA, USA) for 48 h. Human aortic SMCs were starved for 8 h using DMEM containing 1% FBS, followed by the same treatment as human macrophages for 48 h. Then cells were lysed in a lysis buffer containing 50 mmol/L Tris-HCl, pH 7.4, 150 mmol/L NaCl, 2 mmol/L ethylenediaminetetraacetic acid (EDTA), 1% Nonidet P-40 (NP-40), 0.1% (1 g/L) sodium dodecyl sulfate (SDS), 0.5% (5 g/L) sodium deoxycholate, and a protease inhibitor cocktail (Roche Diagnostics Corporation, Indianapolis, IN, USA). Cell lysates were centrifuged at 12 000 r/min for 20 min. Supernatant was collected for protein concentration determination using the BCA protein assay kit (Pierce, Rockford, IL, USA). For analysis, an equal amount of protein from each cell lysate was separated for Western blot analysis with rabbit anti-human MMP-22 polyclonal antibody (1:500 (v/v), ab87066, Abcam, Cambridge, MA, USA) and mouse anti-human β-actin monoclonal antibody (1:3000, sc-81178, Santa Cruz Biotechnology, Inc., Dallas, TX, USA). Human study design 2 This prospective study was carried out in 194 consecutively enrolled CHD patients who had undergone coronary angiography (CAG) from October 2013 to October 2014 at the Department of Cardiology, the First Affiliated Hospital of Zhengzhou University, China. Patients were classified into two groups, including 75 patients with acute coronary syndrome (ACS) and 119 patients with stable angina pectoris (SAP). The ACS group consisted of 27 patients with acute myocardial infarction (AMI) and 48 patients with unstable angina pectoris (UAP). We selected 68 volunteers as controls from 158 consecutively enrolled individuals from the outpatient visits after excluding any of the following criteria: history of cardiovascular diseases; signs of ischemic heart disease; or electrocardiographic (ECG) criteria suggestive of CHD. AMI was diagnosed with the presence of at least two of the following three characteristics from the universal definition of myocardial infarction (Thygesen et al., 2012 2012 ): chest pain or equivalent symptoms; dynamic ECG changes consistent with AMI; and a typical serial increase (to at least three times the upper normal value) and decrease in cardiac necrosis markers such as creatine kinase-myocardial band isoenzyme (CK-MB) and/or troponin-I (Tn-I). UAP was defined by an ECG ST-segment depression of at least 0.1 mV or prominent T-wave inversion in two or more continuous ECG leads in an appropriate clinical setting (chest discomfort or anginal equivalent) without elevation of CK-MB or Tn-I (Anderson et al., 2013 2013 ). SAP was diagnosed as chest pain of at least 6 months’ duration accompanied by evidence of severe coronary artery disease on CAG and by the absence of clinically evident ischemic episodes during the week preceding arteriography (Task Force et al., 2013 2013 ). We also excluded patients with the following conditions to limit potential confounding effects: valvular heart disease, peripheral angiopathy, acute or chronic inflammatory diseases, immunologic diseases, respiratory insufficiency, renal or hepatic dysfunction, malignant neoplasia or terminal cachexia, and history or the presence of neoplastic diseases. The study was approved by the Ethics Committee of the First Affiliated Hospital of Zhengzhou University. All subjects were informed about the protocol at the time of enrollment and consented to study participation. Clinical information and plasma IL18, MMP-22 and -29 measurement 2 Patient information, including age, sex, history of hypertension, diabetes mellitus, hyperlipidemia, cerebrovascular disease, CHD family history, and smoking (consuming tobacco for at least three years), was collected. Blood samples were collected from the peripheral vein into tubes containing EDTA after admission to hospital and 15 min of bed rest. Plasma was prepared by centrifugation at 3000 r/min for 10 min at 4 °C. All samples were stored at −80 °C until the assay. Plasma levels of total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL), high-density lipoprotein (HDL), high-sensitive-C-reactive protein (hs-CRP), N-terminal pro-brain natriuretic peptide (NT-proBNP), and hemoglobin A1c (HbA1c) were determined using standard laboratory procedures at the clinical laboratory of the First Affiliated Hospital of Zhengzhou University, Henan, China. Plasma IL18 (JEB-10092, Nanjing Jin Yibai Biological Science and Technology Co., Ltd., Nanjing, China), MMP-22 (AE98622Hu, Shanghai Lianshuo Biological Technology Co., Ltd., Shanghai, China), and MMP-29 (JEB-12219, Nanjing Jin Yibai Biological Science and Technology Co., Ltd.) levels were determined using enzyme-linked immunosorbent assay (ELISA) kits in duplicates, according to the manufacturer’s instructions. All plasma sample aliquots were thawed only once. Percutaneous coronary intervention, angiographic analysis, and echocardiographic study 2 CAG and percutaneous coronary intervention (PCI) were performed by the Judkins technique with standard equipment. Coronary angiograms were used for quantitative coronary angiographic analysis by two experienced investigators who were unaware of the clinical data. The severity of coronary artery stenosis was qualified by the Gensini score (Gensini, 1983 1983 ). Transthoracic two-dimensional echocardiography was performed by an experienced echocardiographer for all participants on Day 2 after admission, using a digital imaging system (Vivid-7; GE Medical System, Willoughby, Ohio, USA). The left ventricular end-systolic volume (LVESV) and end-diastolic volume (LVEDV) were measured using biplane Simpson’s method, and left ventricular ejection fraction (LVEF, %) was calculated by (LVEDV−LVESV)/LVEDV×100% from the apical four chambers position. Statistical analysis 2 Mean levels of variables were compared across quartiles of IL18, MMP-22 and -29 levels by analysis of variance (ANOVA) for continuous variables and Mann Whitney U test was used to compare levels of these variables between different groups. Biomarker values were logarithmically transformed to reduce skewness. Logistic regression model was used to assess the relationship between CHD status and clinical risk factors. We used a forward selection model-building strategy and knowledge from a thorough literature review to select the covariates for further consideration in the multivariable analysis. Age, sex, smoking, diabetes, and hypertension were adjusted in the multivariable model. To analyze the correlation of plasma levels of IL18, MMP-22 and -29, we used Spearman’s correlation test. All analyses were performed by the SAS software (v.9.3, SAS Institute Cary, NC, USA), and P < 0.05 was considered statistically significant. Results 1 MMP-22 expression in human SMCs and macrophages 2 MMP-22 has been identified for over a decade, but limited information is available besides its known overall expression in the human heart (Anderson et al., 2013 2013 ). It remains unknown whether cardiovascular or inflammatory cells express this protease differently under physiological or pathological conditions, how this protease expression is regulated, and whether its expression correlates with any pathological conditions of the heart. The availability of rabbit anti-human MMP-22 antibody allowed us to detect the expression of this MMP in human aortic SMCs and monocyte-derived macrophages. In human aortic SMCs, IL18 increased the expression of all three isoforms of MMP-22 (Fig. 1a 1a ), derived from alternative splicing (Gururajan et al., 1998 1998 ). In contrast, IL18 did not affect MMP-22 expression in human monocyte-derived macrophages. Human macrophage expressed only the longest isoform of human MMP-22 (Fig. 1b 1b ). This observation suggests a role of IL18 in increasing the expression of MMP-22 in the vasculature of patients with CHD. Due to the lack of human MMP-29-specific antibody, we were unable to test whether IL18 affected MMP-29 expression in human aortic SMCs or macrophages. Therefore, increased plasma and arterial wall IL18 levels in CHD patients may lead to higher plasma and arterial wall expression of MMP-22 (Mallat et al., 2001 2001 ; Blankenberg et al., 2002 2002 ; 2003 2003 ; Gerdes et al., 2002 2002 ; Evans et al., 2007 2007 ; Jefferis et al., 2011 2011 ; 2013 2013 ; Wang et al., 2015 2015 ). (a) Human aortic SMCs were treated without ( n =3) and with ( n =9) recombinant human IL18, followed by MMP-22 immunoblot analysis. (b) Human monocyte-derived macrophages were treated without ( n =3) and with ( n =6) recombinant human IL18, followed by MMP-22 immunoblot analysis. The same blots were re-probed for β-actin to ensure equal protein loading. Arrowheads indicate all three isoforms of human MMP-22 General characteristics of CHD and non-CHD patients 2 A total of 194 patients with CHD (75 ACS patients and 119 SAP patients) and 68 non-CHD volunteers were included in the study. We examined the impact of sex, age, current smoking, diabetes mellitus, hypertension, hyperlipidemia, cerebrovascular disease, and CHD family history between CHD patients and non-CHD volunteers to the risk of CHD. Logistic regression showed that, among all tested common risk factors, sex (odds ratio (OR)=4.981, P =0.017) and age (OR=0.945, P =0.040) showed as significant risk factors to CHD in this population. Hypertension may also be a CHD risk factor, but statistical analysis showed borderline significance (OR=3.802, P =0.050) (Table 1 1 ). Variable OR (95% CI) (CHD vs. non-CHD) P Sex 4.981 (1.336, 18.568) 0.017 Age 0.945 (0.896, 0.997) 0.040 Current smoking 2.000 (0.425, 9.402) 0.380 Diabetes mellitus 0.760 (0.196, 2.951) 0.692 Hypertension 3.802 (1.021, 14.162) 0.050 Hyperlipidemia 0.875 (0.100, 7.646) 0.904 Cerebrovascular disease 0.345 (0.063, 1.889) 0.220 CHD family history 0.532 (0.104, 2.732) 0.450 Plasma IL18, MMP-22 and -29 are independent risk factors of CHD 2 The Mann Whitney U test demonstrated that plasma levels of IL18 were significantly higher in the ACS group than in the control group ((17.20±0.88) ng/dl vs. (8.19±3.16) ng/dl, mean±standard error of the mean (SEM); P =0.011; Fig. 2a 2a ). We also found significantly higher plasma levels of MMP-22 from patients with ACS than those from SAP patients ((2.42±0.14) ng/ml vs. (1.49±0.26) ng/ml, mean±SEM; P =0.034; Fig. 2b 2b ). Likewise, plasma MMP-29 levels were significantly higher in the ACS group ((205.29±24.64) ng/ml, mean±SEM) than in the SAP group ((156.48±18.26) ng/ml, mean±SEM; P =0.038) and control ((112.43±15.56) ng/ml, mean±SEM; P < 0.001) groups (Fig. 2c 2c ). Data are expressed as mean±SEM. P < 0.05 was considered as statistical significance, using Mann Whitney U test Univariate logistic regression analysis showed that plasma IL18, MMP-22 and -29 levels were all significant risk factors of CHD with ORs at 1.131 ( P =0.007), 1.213 ( P =0.040), and 1.198 ( P =0.033), respectively. After adjusting for smoking, diabetes, hypertension, age, and sex, these plasma cytokine and proteinases remained as significant risk factors of CHD (Table 2 2 ). Data are expressed as ln(IL18) (ng/dl), ln(MMP-22) (ng/ml), and ln(MMP-29) (ng/ml) at percentile 50% (25%, 75%). ANOVA test; Logistic regression analysis; Logistic regression analysis after adjusting for smoking, diabetes, hypertension, age, and sex Dependent variable CHD status Logarithmized data # # OR (95% CI) Adjusted OR (95% CI)  ln(IL18)   CHD 0.98 (0.81, 1.42) 2 1.131 (1.027, 1.751) 2 1.021 (1.001, 1.369)   Non-CHD 0.84 (0.00, 1.00)   P 0.002 * * 0.007 ** ** 0.005 *** ***  ln(MMP-22)   CHD 0.15 (0.01, 0.51) 2 1.213 (1.041, 2.529) 2 1.092 (1.013, 1.777)   Non-CHD 0.01 (0.00, 0.06)   P 0.026 * * 0.040 ** ** 0.011 *** ***  ln(MMP-29)   CHD 2.13 (2.01, 2.42) 2 1.198 (1.039, 2.380) 2 1.082 (1.011, 1.775)   Non-CHD 2.04 (1.99, 2.10)   P 0.009 * * 0.033 ** ** 0.012 *** *** An ANOVA test of logarithmized data also indicated that the 194 CHD patients had significantly higher plasma ln(IL18) (0.98 (0.81, 1.42) vs. 0.84 (0.00, 1.00) ng/dl; P =0.002), ln(MMP-22) (0.15, (0.01, 0.51) vs. 0.01 (0.00, 0.06) ng/ml; P =0.026), and ln(MMP-29) (2.13 (2.01, 2.42) vs. 2.04 (1.99, 2.10) ng/ml; P =0.009) levels than those from the 68 non-CHD control patients (Table 2 2 ). Correlations between plasma IL18, MMP-22 and -29 and CHD severity, heart functions, and common plasma CHD biomarkers 2 Univariate Pearson’s correlation analysis using logarithmized plasma IL18, MMP-22 and -29 levels demonstrated that plasma IL18 (coefficient ( r )=0.214, P =0.045) and MMP-22 ( r =0.273, P =0.006) levels were associated with the Gensini scores, as measure of CHD severity and extent. The multivariate Pearson’s correlation test showed that both IL18 ( r =0.246, P =0.031) and MMP-22 ( r =0.286, P =0.012) remained associated with the Gensini scores after adjusting for smoking, diabetes, hypertension, age, and sex (Table 3 3 ). However, the MMP-29 levels were not found to be associated with the Gensini scores under either univariate or multivariate Pearson’s correlation test (Table 3 3 ). Further, none of the tested plasma cytokine or proteinases (IL18, MMP-22 and -29) showed significant correlations with LVEF, LVEDV, or LVESV in this population, before and after adjusting for CHD risk factors including smoking, diabetes, hypertension, age, and sex (Table 3 3 ). Importantly, Spearman’s correlation test showed that the pro-inflammatory IL18 associated strongly and positively with both the MMP-22 ( r =0.845, P < 0.001; Fig. 3a 3a ) and MMP-29 ( r =0.548, P < 0.001; Fig. 3b 3b ) in all tested samples. These human data support our observations from in vitro cultured human SMCs (Fig. 1a 1a ) that IL18 induced MMP-22 expression in these cells. Increased systemic expression of IL18 from CHD patients may be responsible in part for increased plasma MMP-22 and possibly MMP-29. LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVEF, left ventricular ejection fraction. * Adjusted for smoking, diabetes, hypertension, age, and sex 2 Variable 2 Correlation analysis 2 ln(IL18) 2 ln(MMP-22) 2 ln(MMP-29) r P r P r P Gensini score Univariate 0.214 0.045 0.273 0.006 0.177 0.078 Multivariate * 0.246 0.031 0.286 0.012 0.178 0.121 LVEDV Univariate −0.097 0.186 −0.068 0.325 0.031 0.666 Multivariate * −0.090 0.249 −0.063 0.416 0.009 0.911 LVESV Univariate −0.073 0.321 −0.110 0.109 0.037 0.602 Multivariate * −0.054 0.491 −0.080 0.307 0.060 0.440 LVEF Univariate 0.024 0.742 0.085 0.214 −0.019 0.784 Multivariate * −0.002 0.978 0.014 0.862 −0.051 0.515 Both correlation coefficient ( r ) and P values are indicated for each analysis Multivariate Pearson’s correlation analysis showed that plasma MMP-22 was associated significantly with plasma hs-CRP among all other common CHD risk factors, including NT-proBNP, HbA1C, TC, TG, HDL cholesterol (HDL-C), and LDL cholesterol (LDL-C), after adjusting for CHD risk factors smoking, diabetes, hypertension, age, and sex ( r =0.167, P =0.023; Table 4 4 ). Plasma MMP-29 levels were associated significantly, but negatively, with plasma TG in both univariate ( r =−0.165, P =0.012) and multivariate ( r =−0.169, P =0.018) Pearson’s correlation analyses (Table 4 4 ). These observations support the hypothesis that elevated inflammation in CHD patients, as reflected by high plasma hs-CRP and IL18 levels, leads to increased protease expression, such as MMP-22 and many other MMPs and cathepsins and consequent arterial wall remodeling. hs-CRP, high-sensitivity C-reactive protein; NT-proBNP, N-terminal pro-brain natriuretic peptide; HbA1C, hemoglobin A1C; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol. * Adjusted for smoking, diabetes, hypertension, age, and sex 2 Variable 2 Correlation analysis 2 ln(IL18) 2 ln(MMP-22) 2 ln(MMP-29) r P r P r P hs-CRP (mg/L) Univariate 0.112 0.110 0.112 0.091 0.012 0.860 Multivariate * 0.125 0.090 0.167 0.023 0.025 0.731 NT-proBNP (pg/ml) Univariate 0.018 0.807 −0.004 0.959 0.026 0.707 Multivariate * 0.033 0.672 0.012 0.880 −0.003 0.968 HbA1C (%) Univariate −0.116 0.343 −0.017 0.879 0.009 0.938 Multivariate * −0.110 0.422 −0.026 0.850 −0.061 0.658 TC (mmol/L) Univariate 0.069 0.311 0.000 0.997 0.000 0.996 Multivariate * 0.074 0.307 0.076 0.291 0.007 0.920 TG (mmol/L) Univariate −0.056 0.414 −0.058 0.366 −0.165 0.012 Multivariate * −0.069 0.339 0.045 0.536 −0.169 0.018 HDL-C (mmol/L) Univariate 0.035 0.605 0.068 0.295 0.130 0.048 Multivariate * 0.035 0.625 −0.025 0.732 0.103 0.152 LDL-C (mmol/L) Univariate 0.077 0.258 0.036 0.578 0.036 0.582 Multivariate * 0.073 0.309 0.047 0.516 0.014 0.849 Discussion 1 MMPs are among the most common proteases from the arterial wall in patients and experimental animals with atherosclerosis (Loftus et al., 2001 2001 ; Nilsson et al., 2006 2006 ; Lehrke et al., 2009 2009 ; Ma et al., 2014 2014 ; Goncalves et al., 2015 2015 ). However, there has been limited information on MMP-22 and -29 since their initial identification (Gururajan et al., 1998 1998 ; Wu et al., 2007 2007 ). For unknown reasons, there is no study to suggest their matrix substrates, other intracellular and extracellular targets, or action mechanisms, and there is no information of how these proteases are regulated, although both MMPs are expressed in the human heart. Indeed, MMP-22 is expressed predominantly in the human heart (Gururajan et al., 1998 1998 ). There must be a role for this protease to affect the heart functions, by acting on arterial wall matrix proteins or cardiac tissues, or by activating other tissue remodeling proteases, all which remain untested. Alternative splicing leads to three isoforms of human MMP-22 with size differences in either exon 4 or exon 5 (Gururajan et al., 1998 1998 ). Here we showed that IL18 increased the expression of all three isoforms of MMP-22 in human SMCs (Fig. 1a 1a ). In contrast, human macrophages contained only the longest form of MMP-22 with extended exon 4 and IL18 did not affect its expression in macrophages (Fig. 1b 1b ). In addition we do not know why macrophages contained only one MMP-22 isoform. We also do not know whether all three isoforms of MMP-22 are equally active against their substrates or what are the actual substrate(s) of these MMP-22 species. However, these biochemical data support the observations from human plasma samples that: IL18, MMP-22 and -29 from ACS patients all increased concurrently (Fig. 2 2 ); IL18 levels correlated positively with MMP-22 or -29 (Fig. 3 3 ); and hs-CRP levels correlated with MMP-22 in multivariate Pearson’s correlation analyses (Table 4 4 ). Together, these observations suggest that inflammation is involved in promoting the expression of MMP-22 and possibly MMP-29 during atherogenesis and that IL18 is one of those inflammatory regulators of these MMPs in CHD patients. Prior studies demonstrated increased plasma IL18 levels in patients with stroke, myocardial infarction (MI), or CHD (Jefferis et al., 2011 2011 ; 2013 2013 ). Plasma IL18 levels were also higher in patients with heart failure than in those without (Mallat et al., 2004 2004 ), and higher in in-hospital ACS patients with adverse events, including cardiac death, recurrence of unstable angina, re-infarction, life-threatening arrhythmias, and urgent revascularization during hospitalization, than in those without these adverse events (Chalikias et al., 2005 2005 ). As a risk factor, plasma IL18 predicts CHD (Blankenberg et al., 2003 2003 ) and death from cardiovascular causes in CHD patients, regardless of the patient clinical status at admission (Blankenberg et al., 2002 2002 ). In a study of European men, plasma IL18 levels showed no correlations with diabetes, hypertension, smoking, or alcohol consumption, but correlated with TC:HDL ratio, CRP, fibrinogen, and IL6 (Blankenberg et al., 2003 2003 ). Consistent with those prior studies, we also showed higher plasma IL18 in ACS patients (Fig. 2a 2a ) or CHD patients (Table 2 2 ) than non-CHD controls and demonstrated that IL18 is also an independent risk factor of CHD in this Chinese population (Table 2 2 ). Of note, among this population, we found that smoking, diabetes mellitus, and hyperlipidemia were not associated with plasma IL18 (Table 1 1 ), and IL18 levels did not associate with plasma cholesterol levels and diabetic markers (Tables 3 3 and 4 4 ). Similar inconsistent observations were obtained from prior studies. From a French population, plasma IL18 also did not associate with diabetes, smoking, or hypertension (Blankenberg et al., 2003 2003 ), but plasma IL18 levels were found associated with smoking, plasma insulin, and systolic and diastolic blood pressure from the British Regional Heart Study (Jefferis et al., 2011 2011 ). From a large population of British men, plasma IL18 levels were not associated with plasma insulin and glucose levels (Jefferis et al., 2013 2013 ). In contrast, plasma IL18 levels were strongly associated with diabetes and blood pressure from a relatively small population of women from South Africa (Evans et al., 2007 2007 ). Therefore, race and gender may affect the association between IL18 and smoking, diabetes, hypertension, and hyperlipidemia. The mechanism by which IL18 participates in atherosclerosis has been tested in atherosclerosis prone apolipoprotein E-deficient mice. In the absence of T cells, intraperitoneal injection of IL18 increased atherosclerotic lesion expression of IFN-γ and chemokine (C-X-C motif) ligand 16 (chemokine CXCL16) (Tenger et al., 2005 2005 ). Therefore, IL18 may contribute to atherogenesis independent of T cells. Similar to these findings, our prior study showed that IL18-induced expression of IFN-γ and IL6 in macrophages was hundreds of times higher than that from T cells (Wang et al., 2015 2015 ). As an indirect mechanism, IL18-induced production of IFN-γ and IL6 from macrophages may be used to promote MMP-22 and -29 expression in other vascular and inflammatory cells. As a direct mechanism, IL18 may act on vascular cells (Fig. 1a 1a ) or other inflammatory cells, such as monocytes, NK cells, and even cardiomyocytes to induce their expression of MMP-22 and -29 (Quiding-Jarbrink et al., 2001 2001 ; Abraham et al., 2002 2002 ; Gerdes et al., 2002 2002 ; Ishida et al., 2004 2004 ; Reddy et al., 2010 2010 ; Wang et al., 2015 2015 ). A detailed expression profile of MMP-22 and -29 in inflammatory cells, vascular cells, and cardiac cells merits future investigation. References M Abraham , S Shapiro , N Lahat , 等 . The role of IL-18 and IL-12 in the modulation of matrix metalloproteinases and their tissue inhibitors in monocytic cells . Int Immunol , 2002 . 14 ( 12 ): 1449 - 1457 . 12456593 DOI: 10.1093/intimm/dxf108 http://doi.org/10.1093/intimm/dxf108 . The role of IL-18 and IL-12 in the modulation of matrix metalloproteinases and their tissue inhibitors in monocytic cells JL Anderson , CD Adams , EM Antman , 等 . 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines . J Am Coll Cardiol , 2013 . 61 ( 23 ): e179 - e347 . 23639841 DOI: 10.1016/j.jacc.2013.01.014 http://doi.org/10.1016/j.jacc.2013.01.014 . 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines A Arbab-Zadeh , V Fuster . The myth of the “vulnerable plaque”: transitioning from a focus on individual lesions to atherosclerotic disease burden for coronary artery disease risk assessment . J Am Coll Cardiol , 2015 . 65 ( 8 ): 846 - 855 . 25601032 DOI: 10.1016/j.jacc.2014.11.041 http://doi.org/10.1016/j.jacc.2014.11.041 . The myth of the “vulnerable plaque”: transitioning from a focus on individual lesions to atherosclerotic disease burden for coronary artery disease risk assessment S Blankenberg , L Tiret , C Bickel , 等 . Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina . Circulation , 2002 . 106 ( 1 ): 24 - 30 . 12093765 DOI: 10.1161/01.CIR.0000020546.30940.92 http://doi.org/10.1161/01.CIR.0000020546.30940.92 . Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina S Blankenberg , G Luc , P Ducimetiere , 等 . Interleukin-18 and the risk of coronary heart disease in European men: the prospective epidemiological study of myocardial infarction (PRIME) . Circulation , 2003 . 108 ( 20 ): 2453 - 2459 . 14581397 DOI: 10.1161/01.CIR.0000099509.76044.A2 http://doi.org/10.1161/01.CIR.0000099509.76044.A2 . Interleukin-18 and the risk of coronary heart disease in European men: the prospective epidemiological study of myocardial infarction (PRIME) GK Chalikias , DN Tziakas , JC Kaski , 等 . Interleukin-18:interleukin-10 ratio and in-hospital adverse events in patients with acute coronary syndrome . Atherosclerosis , 2005 . 182 ( 1 ): 135 - 143 . 16115484 DOI: 10.1016/j.atherosclerosis.2005.02.002 http://doi.org/10.1016/j.atherosclerosis.2005.02.002 . Interleukin-18:interleukin-10 ratio and in-hospital adverse events in patients with acute coronary syndrome C Cheng , D Tempel , R van Haperen , 等 . Atherosclerotic lesion size and vulnerability are determined by patterns of fluid shear stress . Circulation , 2006 . 113 ( 23 ): 2744 - 2753 . 16754802 DOI: 10.1161/CIRCULATIONAHA.105.590018 http://doi.org/10.1161/CIRCULATIONAHA.105.590018 . Atherosclerotic lesion size and vulnerability are determined by patterns of fluid shear stress EE Creemers , JP Cleutjens , JF Smits , 等 . Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? . Circ Res , 2001 . 89 ( 3 ): 201 - 210 . 11485970 DOI: 10.1161/hh1501.094396 http://doi.org/10.1161/hh1501.094396 . Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? R Elhage , J Jawien , M Rudling , 等 . Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice . Cardiovasc Res , 2003 . 59 ( 1 ): 234 - 240 . 12829194 DOI: 10.1016/S0008-6363(03)00343-2 http://doi.org/10.1016/S0008-6363(03)00343-2 . Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice J Evans , M Collins , C Jennings , 等 . The association of interleukin-18 genotype and serum levels with metabolic risk factors for cardiovascular disease . Eur J Endocrinol , 2007 . 157 ( 5 ): 633 - 640 . 17984243 DOI: 10.1530/EJE-07-0463 http://doi.org/10.1530/EJE-07-0463 . The association of interleukin-18 genotype and serum levels with metabolic risk factors for cardiovascular disease AV Finn , M Nakano , J Narula , 等 . Concept of vulnerable/unstable plaque . Arterioscler Thromb Vasc Biol , 2010 . 30 ( 7 ): 1282 - 1292 . 20554950 DOI: 10.1161/ATVBAHA.108.179739 http://doi.org/10.1161/ATVBAHA.108.179739 . Concept of vulnerable/unstable plaque GG Gensini . A more meaningful scoring system for determining the severity of coronary heart disease . Am J Cardiol , 1983 . 51 ( 3 ): 606 6823874 DOI: 10.1016/S0002-9149(83)80105-2 http://doi.org/10.1016/S0002-9149(83)80105-2 . A more meaningful scoring system for determining the severity of coronary heart disease N Gerdes , GK Sukhova , P Libby , 等 . Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis . J Exp Med , 2002 . 195 ( 2 ): 245 - 257 . 11805151 DOI: 10.1084/jem.20011022 http://doi.org/10.1084/jem.20011022 . Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis I Goncalves , E Bengtsson , HM Colhoun , 等 . Elevated plasma levels of MMP-12 are associated with atherosclerotic burden and symptomatic cardiovascular disease in subjects with type 2 diabetes . Arterioscler Thromb Vasc Biol , 2015 . 35 ( 7 ): 1723 - 1731 . 25953645 DOI: 10.1161/ATVBAHA.115.305631 http://doi.org/10.1161/ATVBAHA.115.305631 . Elevated plasma levels of MMP-12 are associated with atherosclerotic burden and symptomatic cardiovascular disease in subjects with type 2 diabetes R Gururajan , J Grenet , JM Lahti , 等 . Isolation and characterization of two novel metalloproteinase genes linked to the Cdc2L locus on human chromosome 1p36.3 . Genomics , 1998 . 52 ( 1 ): 101 - 106 . 9740677 DOI: 10.1006/geno.1998.5401 http://doi.org/10.1006/geno.1998.5401 . Isolation and characterization of two novel metalloproteinase genes linked to the Cdc2L locus on human chromosome 1p36.3 GK Hansson . Inflammation, atherosclerosis, and coronary artery disease . N Engl J Med , 2005 . 352 ( 16 ): 1685 - 1695 . 15843671 DOI: 10.1056/NEJMra043430 http://doi.org/10.1056/NEJMra043430 . Inflammation, atherosclerosis, and coronary artery disease MP Herman , GK Sukhova , P Libby , 等 . Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling . Circulation , 2001 . 104 ( 16 ): 1899 - 1904 . 11602491 DOI: 10.1161/hc4101.097419 http://doi.org/10.1161/hc4101.097419 . Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling JH Hu , P Touch , J Zhang , 等 . Reduction of mouse atherosclerosis by urokinase inhibition or with a limited-spectrum matrix metalloproteinase inhibitor . Cardiovasc Res , 2015 . 105 ( 3 ): 372 - 382 . 25616415 DOI: 10.1093/cvr/cvv007 http://doi.org/10.1093/cvr/cvv007 . Reduction of mouse atherosclerosis by urokinase inhibition or with a limited-spectrum matrix metalloproteinase inhibitor Y Ishida , K Migita , Y Izumi , 等 . The role of IL-18 in the modulation of matrix metalloproteinases and migration of human natural killer (NK) cells . FEBS Lett , 2004 . 569 ( 1-3 ): 156 - 160 . 15225625 DOI: 10.1016/j.febslet.2004.05.039 http://doi.org/10.1016/j.febslet.2004.05.039 . The role of IL-18 in the modulation of matrix metalloproteinases and migration of human natural killer (NK) cells BJ Jefferis , O Papacosta , CG Owen , 等 . Interleukin 18 and coronary heart disease: prospective study and systematic review . Atherosclerosis , 2011 . 217 ( 1 ): 227 - 233 . 21481392 DOI: 10.1016/j.atherosclerosis.2011.03.015 http://doi.org/10.1016/j.atherosclerosis.2011.03.015 . Interleukin 18 and coronary heart disease: prospective study and systematic review BJ Jefferis , PH Whincup , P Welsh , 等 . Prospective study of IL-18 and risk of MI and stroke in men and women aged 60–79 years: a nested case-control study . Cytokine , 2013 . 61 ( 2 ): 513 - 520 . 23207179 DOI: 10.1016/j.cyto.2012.10.010 http://doi.org/10.1016/j.cyto.2012.10.010 . Prospective study of IL-18 and risk of MI and stroke in men and women aged 60–79 years: a nested case-control study JL Johnson , L Devel , B Czarny , 等 . A selective matrix metalloproteinase-12 inhibitor retards atherosclerotic plaque development in apolipoprotein E-knockout mice . Arterioscler Thromb Vasc Biol , 2011 . 31 ( 3 ): 528 - 535 . 21212406 DOI: 10.1161/ATVBAHA.110.219147 http://doi.org/10.1161/ATVBAHA.110.219147 . A selective matrix metalloproteinase-12 inhibitor retards atherosclerotic plaque development in apolipoprotein E-knockout mice S Katsuda , T Kaji . Atherosclerosis and extracellular matrix . J Atheroscler Thromb , 2003 . 10 ( 5 ): 267 - 274 . 14718743 DOI: 10.5551/jat.10.267 http://doi.org/10.5551/jat.10.267 . Atherosclerosis and extracellular matrix M Kuzuya , K Nakamura , T Sasaki , 等 . Effect of MMP-2 deficiency on atherosclerotic lesion formation in apoE-deficient mice . Arterioscler Thromb Vasc Biol , 2006 . 26 ( 5 ): 1120 - 1125 . 16556856 DOI: 10.1161/01.ATV.0000218496.60097.e0 http://doi.org/10.1161/01.ATV.0000218496.60097.e0 . Effect of MMP-2 deficiency on atherosclerotic lesion formation in apoE-deficient mice M Lehrke , M Greif , UC Broedl , 等 . MMP-1 serum levels predict coronary atherosclerosis in humans . Cardiovasc Diabetol , 2009 . 8 50 19751510 DOI: 10.1186/1475-2840-8-50 http://doi.org/10.1186/1475-2840-8-50 . MMP-1 serum levels predict coronary atherosclerosis in humans P Libby , PM Ridker , GK Hansson , 等 . Inflammation in atherosclerosis: from pathophysiology to practice . J Am Coll Cardiol , 2009 . 54 ( 23 ): 2129 - 2138 . 19942084 DOI: 10.1016/j.jacc.2009.09.009 http://doi.org/10.1016/j.jacc.2009.09.009 . Inflammation in atherosclerosis: from pathophysiology to practice IM Loftus , AR Naylor , PR Bell , 等 . Plasma MMP-9–a marker of carotid plaque instability . Eur J Vasc Endovasc Surg , 2001 . 21 ( 1 ): 17 - 21 . 11170872 DOI: 10.1053/ejvs.2000.1278 http://doi.org/10.1053/ejvs.2000.1278 . Plasma MMP-9–a marker of carotid plaque instability A Luttun , E Lutgens , A Manderveld , 等 . Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth . Circulation , 2004 . 109 ( 11 ): 1408 - 1414 . 14993123 DOI: 10.1161/01.CIR.0000121728.14930.DE http://doi.org/10.1161/01.CIR.0000121728.14930.DE . Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth Y Ma , A Yabluchanskiy , ME Hall , 等 . Using plasma matrix metalloproteinase-9 and monocyte chemoattractant protein-1 to predict future cardiovascular events in subjects with carotid atherosclerosis . Atherosclerosis , 2014 . 232 ( 1 ): 231 - 233 . 24401244 DOI: 10.1016/j.atherosclerosis.2013.09.013 http://doi.org/10.1016/j.atherosclerosis.2013.09.013 . Using plasma matrix metalloproteinase-9 and monocyte chemoattractant protein-1 to predict future cardiovascular events in subjects with carotid atherosclerosis Z Mallat , A Corbaz , A Scoazec , 等 . Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability . Circulation , 2001 . 104 ( 14 ): 1598 - 1603 . 11581135 DOI: 10.1161/hc3901.096721 http://doi.org/10.1161/hc3901.096721 . Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability Z Mallat , C Heymes , A Corbaz , 等 . Evidence for altered interleukin (IL)-18 pathway in human heart failure . FASEB J , 2004 . 18 ( 14 ): 1752 - 1754 . 15371332 DOI: 10.1096/fj.04-2426fje http://doi.org/10.1096/fj.04-2426fje . Evidence for altered interleukin (IL)-18 pathway in human heart failure AC Newby . Dual role of matrix metalloproteinases (matrixins) in in timal thickening and atherosclerotic plaque rupture . Physiol Rev , 2005 . 85 ( 1 ): 1 - 31 . 15618476 DOI: 10.1152/physrev.00048.2003 http://doi.org/10.1152/physrev.00048.2003 . Dual role of matrix metalloproteinases (matrixins) in in timal thickening and atherosclerotic plaque rupture L Nilsson , L Jonasson , J Nijm , 等 . Increased plasma concentration of matrix metalloproteinase-7 in patients with coronary artery disease . Clin Chem , 2006 . 52 ( 8 ): 1522 - 1527 . 16762997 DOI: 10.1373/clinchem.2006.067439 http://doi.org/10.1373/clinchem.2006.067439 . Increased plasma concentration of matrix metalloproteinase-7 in patients with coronary artery disease NJ Pagidipati , TA Gaziano . Estimating deaths from cardiovascular disease: a review of global methodologies of mortality measurement . Circulation , 2013 . 127 ( 6 ): 749 - 756 . 23401116 DOI: 10.1161/circulationaha.112.128413 http://doi.org/10.1161/circulationaha.112.128413 . Estimating deaths from cardiovascular disease: a review of global methodologies of mortality measurement M Quiding-Jarbrink , DA Smith , GJ Bancroft . Production of matrix metalloproteinases in response to mycobacterial infection . Infect Immun , 2001 . 69 ( 9 ): 5661 - 5670 . 11500442 DOI: 10.1128/IAI.69.9.5661-5670.2001 http://doi.org/10.1128/IAI.69.9.5661-5670.2001 . Production of matrix metalloproteinases in response to mycobacterial infection VS Reddy , SD Prabhu , S Mummidi , 等 . Interleukin-18 induces EMMPRIN expression in primary cardiomyocytes via JNK/Sp1 signaling and MMP-9 in part via EMMPRIN and through AP-1 and NF-κB activation . Am J Physiol Heart Circ Physiol , 2010 . 299 ( 4 ): H1242 - H1254 . 20693392 DOI: 10.1152/ajpheart.00451.2010 http://doi.org/10.1152/ajpheart.00451.2010 . Interleukin-18 induces EMMPRIN expression in primary cardiomyocytes via JNK/Sp1 signaling and MMP-9 in part via EMMPRIN and through AP-1 and NF-κB activation R Ross . Atherosclerosis–an inflammatory disease . N Engl J Med , 1999 . 340 ( 2 ): 115 - 126 . 9887164 DOI: 10.1056/NEJM199901143400207 http://doi.org/10.1056/NEJM199901143400207 . Atherosclerosis–an inflammatory disease G Siasos , D Tousoulis , S Kioufis , 等 . Inflammatory mechanisms in atherosclerosis: the impact of matrix metalloproteinases . Curr Top Med Chem , 2012 . 12 ( 10 ): 1132 - 1148 . 22519444 DOI: 10.2174/1568026611208011132 http://doi.org/10.2174/1568026611208011132 . Inflammatory mechanisms in atherosclerosis: the impact of matrix metalloproteinases M Task Force , G Montalescot , U Sechtem , 等 . 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology . Eur Heart J , 2013 . 34 ( 38 ): 2949 - 3003 . 23996286 DOI: 10.1093/eurheartj/eht296 http://doi.org/10.1093/eurheartj/eht296 . 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology C Tenger , A Sundborger , J Jawien , 等 . IL-18 accelerates atherosclerosis accompanied by elevation of IFN-γ and CXCL16 expression independently of T cells . Arterioscler Thromb Vasc Biol , 2005 . 25 ( 4 ): 791 - 796 . 15604417 DOI: 10.1161/01.ATV.0000153516.02782.65 http://doi.org/10.1161/01.ATV.0000153516.02782.65 . IL-18 accelerates atherosclerosis accompanied by elevation of IFN-γ and CXCL16 expression independently of T cells K Thygesen , JS Alpert , AS Jaffe , 等 . Third universal definition of myocardial infarction . J Am Coll Cardiol , 2012 . 60 ( 16 ): 1581 - 1598 . 22958960 DOI: 10.1016/j.jacc.2012.08.001 http://doi.org/10.1016/j.jacc.2012.08.001 . Third universal definition of myocardial infarction J Wang , C Sun , N Gerdes , 等 . Interleukin 18 function in atherosclerosis is mediated by the interleukin 18 receptor and the Na-Cl co-transporter . Nat Med , 2015 . 21 ( 7 ): 820 - 826 . 26099046 DOI: 10.1038/nm.3890 http://doi.org/10.1038/nm.3890 . Interleukin 18 function in atherosclerosis is mediated by the interleukin 18 receptor and the Na-Cl co-transporter S Wu , J Chen , J Feder , 等 . 2007 . Compliance with ethics guidelines Dong-Yi JIN, Cong-Lin LIU, Jun-Nan TANG, Zhao-Zhong ZHU, Xue-Xi XUAN, Xiao-Dan ZHU, Yun-Zhe WANG, Tian-Xia ZHANG, De-Liang SHEN, Xiao-Fang WANG, Guo-Ping SHI, and Jin-Ying ZHANG declare that they have no conflict of interest. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5). Informed consent was obtained from all patients for being included in the study. 10.1631/jzus.B1700073 Project supported by the University of Science and Technology Innovation Team of Henan (No. 14IRTSTHN018), the Science and Technology Talents Team Construction Program of Zhengzhou City-Science and Technology Talents (No. 131PLJRC670), China, and the National Institutes of Health (Nos. HL60942 and HL123568), USA 2017-02-11 2017-05-01 2022-01-05 Copyright © Zhejiang University and Springer-Verlag Berlin Heidelberg 2017 2017 Journal of Zhejiang University-SCIENCE B (Biomedicine and Biotechnology) 08 18